![]() | Up a level |
Journal Article
Estenfelder, S., Tausch, E., Huber, H., Bloehdorn, J., Cymbalista, F., Leblond, V., Delmer, A., Ibach, S., Choquet, S., Dartigeas, C., Cazin, B., Tournilhac, O., Pegourie, B., Seiler, T., Soekler, M., Zirlik, K., Alt, J., Schetelig, J., Hallek, M., Dreger, P., Doehner, H. and Stilgenbauer, S. (2016). MUTATION ANALYSIS BY TARGETED NEXT GENERATION SEQUENCING IN ULTRA HIGH RISK CLL PATIENTS TREATED WITHIN THE CLL2O STUDY. Haematologica, 101. S. 228 - 230. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Stratmann, J. A., Hornetz, S., Griesinger, F., Wolf, J., Christoph, D. C., Sackmann, S., Spengler, W., Bischoff, H., Schaefer, M., Alt, J., Mlueller, A., Laack, E., Kimmich, M. and Sebastian, M. (2017). An expanded access program of osimertinib (Tagrisso) in patients with advanced non-small cell lung cancer: data report from Germany. Oncol. Res. Treat., 40. S. 170 - 171. BASEL: KARGER. ISSN 2296-5262